Tsunezuka Yoshio, Tanaka Nobuyoshi, Fujimori Hideki, Togashi Yuki, Baba Satoko, Takeuchi Kengo, Katayanagi Kazuyoshi, Kurumaya Hiroshi, Kitade Hironori, Atagi Shinji, Yano Seiji
Department of General Thoracic Surgery, Ishikawa Prefectural Central Hospital.
Pathology Project for Molecular Targets, The Cancer Institute, Japanese Foundation for Cancer Research.
J Med Invest. 2017;64(3.4):305-307. doi: 10.2152/jmi.64.305.
A 36-year-old male was found two nodules in the right lower lobe of the lung. After the surgical resection, both lesions were diagnosed as invasive adenocarcinomas. One lesion was primarily lepidic growth component with EGFR-L858R mutation, and the other was micropapillary component with ALK translocation accompanying mediastinal lymphnode metastases. While he experienced disease recurrence, the disease was controlled by an ALK inhibitor, given based on the findings of surgical specimens. This is the first case who had two simultaneous lung cancers with EGFR mutation and ALK translocation in each respective lesion, and was successfully treated with ALK inhibitor at the post-surgical recurrence. J. Med. Invest. 64: 305-307, August, 2017.
一名36岁男性在右下肺发现两个结节。手术切除后，两个病灶均被诊断为浸润性腺癌。一个病灶主要为鳞屑样生长成分且伴有EGFR-L858R突变，另一个为微乳头成分且伴有ALK易位并伴有纵隔淋巴结转移。虽然他出现了疾病复发，但基于手术标本的检查结果给予ALK抑制剂后，疾病得到了控制。这是首例每个病灶分别存在EGFR突变和ALK易位且同时患有两种肺癌的病例，术后复发时使用ALK抑制剂成功治愈。《医学调查杂志》2017年8月第64卷：305 - 307页
